Last updated on November 2019

A Study of Durvalumab or Tremelimumab Monotherapy or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma


Brief description of study

This is a multicenter, open-label, stratified, randomized study to evaluate the safety, tolerability, antitumor activity, PK, pharmacodynamics, and immunogenicity of durvalumab or tremelimumab monotherapy, or durvalumab in combination with tremelimumab or bevacizumab in advanced hepatocellular carcinoma.

Clinical Study Identifier: NCT02519348

Find a site near you

Start Over

Research Site

Hong Kong, Hong Kong
  Connect »

Research Site

Sha Tin, Hong Kong
5.77miles
  Connect »